A tighter archive for life-science signals.
Search once, then narrow by source or topic.
<a href="https://www.fiercebiotech.com/biotech/bayers-asundexian-cuts-stroke-risk-phase-3-reviving-hopes-fxia-class" hreflang="en">Bayer's asundexian cuts stroke risk in phase 3, reviving hopes for FXIa class</a>
Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has s...
Hepatic zonation determines tumorigenic potential of mutant β-catenin
Nature, Published online: 19 November 2025; doi:10.1038/s41586-025-09733-1Zonal positioning in the liver determines whether the CTNNB1 oncogene can induce liver cancer.
FDA investigates child death potentially related to Takeda's enzyme replacement therapy
The FDA said Friday that it is looking into a pediatric patient’s death that appears to be related to Takeda’s Adzynma, which is a treatment for a rare genetic blood di...
Roche Gives Glimpse of Cancer Genomics Potential of New Axelios Sequencer - GenomeWeb
Roche Gives Glimpse of Cancer Genomics Potential of New Axelios Sequencer GenomeWeb
Developing a path forward in cancer cachexia
Pfizer scientists have been working to advance understanding of – and potential treatments for – cachexia.
Thermo Fisher Scientific's Valuation: Assessing Growth Potential After New Facility and Nalgene Product Launches - Yahoo Finance
Thermo Fisher Scientific's Valuation: Assessing Growth Potential After New Facility and Nalgene Product Launches Yahoo Finance
Unlocking the Potential of PROTACs in Drug Discovery - Technology Networks
Unlocking the Potential of PROTACs in Drug Discovery Technology Networks
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page